Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
May 07, 2024 08:00 ET
|
Creyon Bio, Inc.
AI-informed drug design enabled approval to dose within one year of project initiation Data highlight use of AI to engineer investigative allele selective antisense oligonucleotide treatment for baby...
Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases
May 01, 2024 08:00 ET
|
Creyon Bio, Inc.
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C. and SEATTLE, May 01, 2024 (GLOBE NEWSWIRE) -- Creyon Bio, Inc. ("Creyon"), a drug development company that engineers Oligonucleotide-Based Medicines (OBMs)...